 |
|
Implications of Peritoneal Cytology for Pancreatic Cancer Management
Martin A. Makary, MD, MPH;
Andrew L. Warshaw, MD;
Barbara A. Centeno, MD;
Christopher G. Willett, MD;
David W. Rattner, MD;
Carlos Fernández-del Castillo, MD
Arch Surg. 1998;133:361-365.
Objective To assess the implications of positive cytology for malignant cells (positive results) from peritoneal washings in the management of patients with pancreatic cancer.
Design Retrospective cohort study.
Setting Referral practice in a university hospital.
Patients A total of 32 consecutive pancreatic cancer patients with positive results from peritoneal washings during a 4-year period, 17 with visible biopsy-proven intra-abdominal metastases at the time of laparoscopy or laparotomy and 15 without visible metastases. A treatment-matched control group of 30 patients was randomly selected from a group of 105 patients with negative cytology for malignant cells (negative results) from peritoneal-fluid cytology.
Interventions Eight of 17 patients with visible metastases underwent treatment with chemotherapy, radiation, or both; 13 of the 15 patients with no visible metastases underwent further treatment, including pancreatic resection in 2 patients and external beam radiation in 13 patients (3 with intraoperative radiation therapy).
Main Outcome Measures Time to metastases and mortality.
Results Median survival among patients with and without visible metastasis was 7.8 months and 8.6 months, respectively (P=.95), despite the fact that patients without visible metastases received more treatment. Patients without visible metastases at presentation were found to have metastatic disease as documented by computed tomographic scan or subsequent laparotomy at a median time of 2.9 months. The survival of treatment-matched patients with negative cytology was significantly longer (median, 13.5 months; P=.04).
Conclusions Pancreatic cancer patients with peritoneal micrometastases have a dismal outcome even without macroscopic metastases. Since these patients do not benefit from local therapy, the finding of a positive result from peritoneal-fluid cytologic testing contraindicates further irradiation or surgery, except for specific complications.
From the Departments of Surgery (Drs Makary, Warshaw, Rattner, and Fernández-del Castillo), Pathology (Dr Centeno), and Radiation Oncology (Dr Willett), Massachusetts General Hospital, Harvard Medical School, Boston.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review
Stefanidis et al.
Ann Oncol 2006;17:189-199.
ABSTRACT
| FULL TEXT
Colocalization of the Tetraspanins, CO-029 and CD151, with Integrins in Human Pancreatic Adenocarcinoma: Impact on Cell Motility
Gesierich et al.
Clin. Cancer Res. 2005;11:2840-2852.
ABSTRACT
| FULL TEXT
Prognostic Value of Cytologic Examination of Peritoneal Washings in Pancreatic Cancer
Konishi et al.
Arch Surg 2002;137:475-480.
ABSTRACT
| FULL TEXT
Impact of Laparoscopic Staging in the Treatment of Pancreatic Cancer
Jimenez et al.
Arch Surg 2000;135:409-415.
ABSTRACT
| FULL TEXT
Invited Critique: Comparison of Magnetic Resonance and Endoscopic Retrograde Cholangiopancreatography in Malignant Pancreaticobiliary Obstruction: Invited Critique
Sarr
Arch Surg 1999;134:1007-1007.
FULL TEXT
Disseminated Tumor Cells in Pancreatic Cancer Patients Detected by Immunocytology: A New Prognostic Factor
Vogel et al.
Clin. Cancer Res. 1999;5:593-599.
ABSTRACT
| FULL TEXT
|
